Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) EBT Margin (2021 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed EBT Margin for 5 consecutive years, with 83.03% as the latest value for Q4 2025.

  • Quarterly EBT Margin rose 2068.0% to 83.03% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 103.31% through Dec 2025, up 9666.0% year-over-year, with the annual reading at 103.31% for FY2025, 9669.0% up from the prior year.
  • EBT Margin for Q4 2025 was 83.03% at Rhythm Pharmaceuticals, up from 102.91% in the prior quarter.
  • The five-year high for EBT Margin was 187874.29% in Q1 2021, with the low at 14748.54% in Q2 2021.
  • Average EBT Margin over 5 years is 7961.24%, with a median of 182.8% recorded in 2023.
  • Peak annual rise in EBT Margin hit 1425364bps in 2022, while the deepest fall reached -19138103bps in 2022.
  • Over 5 years, EBT Margin stood at 2798.84% in 2021, then surged by 119bps to 527.99% in 2022, then tumbled by -132bps to 170.99% in 2023, then skyrocketed by 39bps to 103.71% in 2024, then grew by 20bps to 83.03% in 2025.
  • According to Business Quant data, EBT Margin over the past three periods came in at 83.03%, 102.91%, and 95.45% for Q4 2025, Q3 2025, and Q2 2025 respectively.